[go: up one dir, main page]

GT201300096A - Composiciones farmaceuticas que contienen un inhibidor de dgat1 - Google Patents

Composiciones farmaceuticas que contienen un inhibidor de dgat1

Info

Publication number
GT201300096A
GT201300096A GT201300096A GT201300096A GT201300096A GT 201300096 A GT201300096 A GT 201300096A GT 201300096 A GT201300096 A GT 201300096A GT 201300096 A GT201300096 A GT 201300096A GT 201300096 A GT201300096 A GT 201300096A
Authority
GT
Guatemala
Prior art keywords
pharmaceutical compositions
compositions containing
dgat1 inhibitor
properties
dgat1
Prior art date
Application number
GT201300096A
Other languages
English (en)
Inventor
Weng Hong
Kumaraperumal Natrajan
Nause Richard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44908106&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201300096(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT201300096A publication Critical patent/GT201300096A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UNA COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE A) UNA CANTIDAD TERAPÉUTICAMENTE EFICAZ DE UN COMPUESTO DE FÓRMULA (I), O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO, B) UNO O MÁS, POR EJEMPLO 1, 2 O 3, AGENTES TENSIOACTIVOS CON PROPIEDADES LUBRICANTES C) UNO O MÁS, POR EJEMPLO 1, 2 O 3, AGLUTINANTES EN SECO CON PROPIEDADES DESINTEGRADORAS D) UNO O MÁS, POR EJEMPLO 1, 2 O 3, RELLENOS, Y E) UNO O MÁS, POR EJEMPLO 1, 2 O 3, DISGREGANTES.
GT201300096A 2010-10-14 2013-04-11 Composiciones farmaceuticas que contienen un inhibidor de dgat1 GT201300096A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39310310P 2010-10-14 2010-10-14

Publications (1)

Publication Number Publication Date
GT201300096A true GT201300096A (es) 2014-07-08

Family

ID=44908106

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201300096A GT201300096A (es) 2010-10-14 2013-04-11 Composiciones farmaceuticas que contienen un inhibidor de dgat1

Country Status (30)

Country Link
US (5) US20130190354A1 (es)
EP (1) EP2627319B1 (es)
JP (1) JP6060081B2 (es)
KR (1) KR20130100311A (es)
CN (1) CN103179957B (es)
AR (1) AR083417A1 (es)
AU (1) AU2011316003B2 (es)
BR (1) BR112013008757A2 (es)
CA (1) CA2813781C (es)
CL (1) CL2013001001A1 (es)
CO (1) CO6710915A2 (es)
DK (1) DK2627319T3 (es)
EC (1) ECSP13012755A (es)
ES (1) ES2712064T3 (es)
GT (1) GT201300096A (es)
HU (1) HUE043524T2 (es)
IL (1) IL225434A0 (es)
MA (1) MA34599B1 (es)
MX (1) MX2013004162A (es)
NZ (1) NZ608558A (es)
PE (1) PE20140375A1 (es)
PH (1) PH12013500695A1 (es)
PL (1) PL2627319T3 (es)
PT (1) PT2627319T (es)
RU (1) RU2595866C2 (es)
SG (1) SG189078A1 (es)
SI (1) SI2627319T1 (es)
TR (1) TR201902435T4 (es)
WO (1) WO2012051488A1 (es)
ZA (1) ZA201302108B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR083417A1 (es) 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US9108956B2 (en) * 2012-04-27 2015-08-18 Novartis Ag Cyclic ether DGAT1 inhibitorscyclic ether DGAT1 inhibitors
WO2013169648A1 (en) * 2012-05-07 2013-11-14 Novartis Ag Pharmaceutical combinations comprising a dgat1 inhibtor and a triglyceride lowering drug
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
CN114099496A (zh) 2015-03-13 2022-03-01 艾斯柏伦治疗公司 含etc1002和依泽替米贝的组合及治疗方法
MA41793A (fr) 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
JP2018534323A (ja) 2015-11-19 2018-11-22 シニュー・ファーマ・インコーポレイテッドＳｉＮｅｗ Ｐｈａｒｍａ Ｉｎｃ． 脂肪肝の予防または処置用医薬組成物
US11975002B2 (en) 2016-03-04 2024-05-07 Taiho Pharmaceutical Co., Ltd. Preparation and composition for treatment of malignant tumors
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
US20180338922A1 (en) * 2017-05-26 2018-11-29 Esperion Therapeutics, Inc. Fixed dose formulations
US10632092B2 (en) 2017-08-30 2020-04-28 First Fruits Business Ministry, Llc Composition for and method to increase serum adiponectin and reduce body fat
CN111936137B (zh) * 2018-03-16 2023-09-08 安济药业公司 用于治疗严重便秘的组合物和方法
AU2019239404B2 (en) * 2018-03-19 2021-12-23 Taiho Pharmaceutical Co., Ltd. Pharmaceutical composition including sodium alkyl sulfate

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE271863T1 (de) 1995-11-14 2004-08-15 Abbott Gmbh & Co Kg Schilddrüsenhormone enthaltende stabilisierte arzneimittel und verfahren
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
DE19816070A1 (de) * 1998-04-09 1999-10-14 Aventis Res & Tech Gmbh & Co Retardtablette hergestellt aus linearen wasserunlöslichen Polysacchariden
WO2003053416A1 (en) * 2001-12-21 2003-07-03 Pfizer Products Inc. Directly compressible formulations of azithromycin
CN101198333A (zh) * 2005-04-19 2008-06-11 拜尔药品公司 芳烷基酸衍生物及其用途
KR101219042B1 (ko) * 2005-12-06 2013-01-07 삼성디스플레이 주식회사 반투과형 액정 표시 장치
CN101365432B (zh) * 2005-12-16 2011-06-22 默沙东公司 二肽基肽酶-4抑制剂与二甲双胍的组合的药物组合物
AU2007223278A1 (en) * 2006-03-06 2007-09-13 Wyeth Tablet formulations and processes
US20070224258A1 (en) 2006-03-22 2007-09-27 Bunick Frank J Dosage forms having a randomized coating
PL2004607T3 (pl) * 2006-03-31 2012-03-30 Novartis Ag Pochodne kwasu (4-(4-[6-(trifluorometylopirydyn-3-yloamino)-N-zawierające-heteroarylo]-fenylo)-cykloheksylo)-octowego i ich farmaceutyczne zastosowania
BRPI0719352A2 (pt) 2006-11-29 2017-10-24 Abbott Lab inibidores de enzima diacilglicerol o-aciltransferase tipo 1
US20080145425A1 (en) * 2006-12-15 2008-06-19 Pliva Research & Development Limited Pharmaceutical composition of zolpidem
NZ580660A (en) 2007-04-30 2012-02-24 Abbott Lab Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
US8283331B2 (en) * 2007-10-09 2012-10-09 Children's Medical Center Corporation Methods to regulate miRNA processing by targeting Lin-28
SMT201700416T1 (it) * 2009-03-31 2017-11-15 Ligand Pharm Inc Antagonista di bifenilsolfonammide del recettore di endotelina ed angiotensina ii per il trattamento della glomerulosclerosi
ES2586127T3 (es) * 2010-03-30 2016-10-11 Novartis Ag Usos de inhibidores de DGAT1
AR083417A1 (es) 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor

Also Published As

Publication number Publication date
MX2013004162A (es) 2014-12-08
RU2013121795A (ru) 2014-11-20
CA2813781C (en) 2018-08-07
SI2627319T1 (sl) 2019-04-30
CN103179957B (zh) 2016-05-18
AU2011316003A1 (en) 2013-04-11
PE20140375A1 (es) 2014-03-19
SG189078A1 (en) 2013-05-31
PL2627319T3 (pl) 2019-05-31
US20200230062A1 (en) 2020-07-23
PH12013500695A1 (en) 2017-08-09
BR112013008757A2 (pt) 2020-09-01
RU2595866C2 (ru) 2016-08-27
NZ608558A (en) 2015-03-27
EP2627319B1 (en) 2018-11-21
CL2013001001A1 (es) 2013-10-25
CN103179957A (zh) 2013-06-26
AU2011316003B2 (en) 2015-03-19
CA2813781A1 (en) 2012-04-19
PT2627319T (pt) 2019-02-27
DK2627319T3 (en) 2019-03-18
US20150320687A1 (en) 2015-11-12
AR083417A1 (es) 2013-02-21
IL225434A0 (en) 2013-06-27
ES2712064T3 (es) 2019-05-09
US20180243222A1 (en) 2018-08-30
US20130190354A1 (en) 2013-07-25
CO6710915A2 (es) 2013-07-15
HUE043524T2 (hu) 2019-08-28
JP6060081B2 (ja) 2017-01-11
US20160374947A1 (en) 2016-12-29
WO2012051488A1 (en) 2012-04-19
ZA201302108B (en) 2013-11-27
US10646446B2 (en) 2020-05-12
JP2013539794A (ja) 2013-10-28
MA34599B1 (fr) 2013-10-02
ECSP13012755A (es) 2014-01-31
US11304907B2 (en) 2022-04-19
EP2627319A1 (en) 2013-08-21
KR20130100311A (ko) 2013-09-10
TR201902435T4 (tr) 2019-03-21

Similar Documents

Publication Publication Date Title
GT201300096A (es) Composiciones farmaceuticas que contienen un inhibidor de dgat1
MX2020004932A (es) Compuestos utiles para inhibir a cdk7.
BR112018003026A2 (pt) composições compreendendo um inibidor de pi3k e um inibidor de hdac
AR090456A1 (es) Combinaciones farmaceuticas que comprenden un analogo de tionucleotidos
BR112015023827A2 (pt) composições de limpeza contendo uma poliéter amina
SV2008003088A (es) Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen
UY32730A (es) Inhibidores de cyp17
UY32490A (es) Inhibidores de beta-secretasa
PE20120250A1 (es) Composicion farmaceutica que comprende derivados de glucopiranosil difenilmetano, forma farmaceutica de la misma, procedimiento para su preparacion
PE20160605A1 (es) Formulaciones de inhibidores de la syk
CL2012001821A1 (es) Compuestos derivados de 5-alquinil-pirimidinas, inhibidores de quinasas; composiciones farmaceuticas que los contienen; y su uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
RS53301B (en) TIOACETATE COMPOUNDS, COMPOSITIONS AND USE PROCEDURES
CL2011002433A1 (es) Compuestos tetraciclicos, inhibidores de alk; composicion farmaceutica que comprende dichos compuestos, utiles en la profilaxis o el tratamiento de cancer, metastasis de cancer, depresion o un trastorno de la funcion cognitiva.
UY31261A1 (es) Imidazopiridinonas, composiciones que las contienen, procedimientos para su preparacion, intermedios utilizados en tales procedimientos y aplicaciones.
CR20140134A (es) Composiciones farmacéuticas
CL2017001650A1 (es) Derivados de 5-[(piperazina-1-yl)-3-oxo-propilo]-imidazolidina-2,4-dionan como inhibidores adamts para el tratamiento oesteoartritis.
CO6501183A2 (es) Piperidinas sustituidas como antagonistas de ccr3
ECSP12012290A (es) Formulaciones farmacéuticas
BR112014001600A2 (pt) composto inibidor do trajeto de sinalização notch
BR112013032711A2 (pt) composições farmacêuticas compreendendo sulbactam e inibidor de beta-lactamase
UA109290C2 (uk) Спільні кристали і солі інгібіторів ccr3
UY37837A (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
PE20151051A1 (es) Formulaciones de liberacion modificada para oprozomib
SG158091A1 (en) Imidazoazepinone compounds